# KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
Canonical URL: https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-the-burden-of-injectable-on-demand-treatment-in-young-children-with-hereditary-angioedema
Ticker: KALV
Company: KalVista Pharmaceuticals, Inc.
Source: KalVista Pharmaceuticals, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.kalvista.com
## Summary

Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28,

## Article Body
Presentations at ISPOR and the Eastern Allergy Conference highlight substantial treatment burden, caregiver anxiety, delayed or untreated HAE attacks, and high healthcare resource utilization among children aged 2–11 living with HAE FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 28,
## Recent Company News
- 2026-06-25 13:46 EST — [Chiesi Group Completes Acquisition of KalVista Pharmaceuticals](https://biopharmsignal.com/news/KALV/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-the-burden-of-injectable-on-demand-treatment-in-young-children-with-hereditary-angioedema) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-present-at-upcoming-investor-conferences) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-presents-new-data-highlighting-high-patient-satisfaction-and-evolving-treatment-trends-with-ekterlyr-sebetralstat) — Source: KalVista Pharmaceuticals, Inc.
- 2026-06-25 13:46 EST — [KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026](https://biopharmsignal.com/news/KALV/kalvista-pharmaceuticals-to-report-eight-months-fiscal-year-2025-financial-results-and-provide-corporate-update-on-march-25-2026) — Source: KalVista Pharmaceuticals, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)